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ABSTRACT
Introduction: Tobacco smoking claims 700 000 lives
every year in Europe and the cost of tobacco smoking in
the EU is estimated between €98 and €130 billion
annually; direct medical care costs and indirect costs
such as workday losses each represent half of this
amount. Policymakers all across Europe are in need of
bespoke information on the economic and wider returns
of investing in evidence-based tobacco control,
including smoking cessation agendas. EQUIPT is
designed to test the transferability of one such
economic evidence base—the English Tobacco Return
on Investment (ROI) tool—to other EU member states.
Methods and analysis: EQUIPT is a multicentre,
interdisciplinary comparative effectiveness research
study in public health. The Tobacco ROI tool already
developed in England by the National Institute for
Health and Care Excellence (NICE) will be adapted to
meet the needs of European decision-makers, following
transferability criteria. Stakeholders’ needs and intention
to use ROI tools in sample countries (Germany,
Hungary, Spain and the Netherlands) will be analysed
through interviews and surveys and complemented by
secondary analysis of the contextual and other factors.
Informed by this contextual analysis, the next phase will
develop country-specific ROI tools in sample countries
using a mix of economic modelling and Visual Basic
programming. The results from the country-specific ROI
models will then be compared to derive policy
proposals that are transferable to other EU states,
from which a centralised web tool will be developed.
This will then be made available to stakeholders to
cater for different decision-making contexts across
Europe.
Ethics and dissemination: The Brunel University
Ethics Committee and relevant authorities in each of the
participating countries approved the protocol. EQUIPT
has a dedicated work package on dissemination,
focusing on stakeholders’ communication needs.
Results will be disseminated via peer-reviewed
publications, e-learning resources and policy briefs.
INTRODUCTION
Globally, tobacco smoking presents a signifi-
cant problem, both in terms of the health of
the population and the wider economic
impact. No corner of the world is untouched
by the effects of tobacco consumption and, in
the EU alone, 28% of the population smokes,
increasing to 29% in those aged 15–24 years.
This results in considerable smoking-related
socioeconomic inequalities across all EU
member states, which translates to nearly
700 000 premature deaths every year.1 Tobacco
use is estimated to cost the European
Community between €98 and €130 billion
annually, with direct medical care costs and
indirect costs (eg, workday losses) both repre-
senting half of this amount. These costs repre-
sented just above 1% of the EU Gross
Domestic Product in 2000. Each EU resident
(smoker or non-smoker) therefore bears a cost
between €211 and €281 per year as the conse-
quence of tobacco smoking in the region.2
The WHO Framework Convention on
Tobacco Control (WHO FCTC) places a
greater value on efforts that can help to
reduce smoking prevalence and recommends
Strengths and limitations of this study
▪ EQUIPT is a rare multidisciplinary study designed
to test the transferability of economic evidence
around tobacco control.
▪ This study will provide evidence-based, practical
and customisable decision-support tools to EU
stakeholders.
▪ Unavailability of intervention effectiveness data
on the full range of recommended activities and
strategies may limit the scope of this research.
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that countries should implement evidence-based, compre-
hensive tobacco-control measures.3 The WHO FCTC has
been ratified by all EU member states, and therefore
efforts have been increasingly directed towards tackling
tobacco smoking at all levels across the European
Community through evidence-based interventions.4
A large, robust and consistent evidence base indicates
that co-ordinated, high impact and comprehensive
approaches are the most effective way to reduce smoking
initiation, prevalence and intensity of consumption.5 6
However, policymakers and public health procurers often
lack the data—and the financial justification—that can
help them to make the case for comprehensive or other
more focused investments to tackle the scourge of
tobacco. In England, for example, the newly implemented
Health and Social Care (2012) Act has placed a much
greater role for Local Authorities in health prevention
and, given the austere climate, this has resulted in more
demand for information relating to the cost-effectiveness
and return on investment (ROI) of tobacco control mea-
sures. Policymakers find it “difficult to present a business
case for investing in public health interventions, due to a
perceived lack of relevant data.”7 This suggests that policy-
makers want to know the following two sets of questions:
(1) If I were to invest money in providing several interven-
tions now in the anticipation (based on current practice)
that a certain number of smokers would eventually take up
those interventions, what would be the extent of the
return on my investment ‘package’ in the short, medium
and long terms; and (2) What if I change the allocation of
services (ie, shift the pattern of current uptake)?
To provide tobacco control policymakers and public
health procurers with predictions of likely returns on
investment, locally, regionally and nationally, arising
from the funding of different tobacco control initiatives,
Brunel University together with the National Institute of
Health and Care Excellence (NICE) and regional
tobacco control organisations in the UK have developed
and tested a ‘ROI’ tool.8 The ROI tool is essentially a
Markov model implemented in Microsoft Excel and is
designed to provide measures of uncertainty around the
ROI estimates via probabilistic sensitivity analysis. In an
era of significant constraints on the public purse, this
tool can contribute to making a powerful case for public
health investments. The scarcity of relevant input data,
however, poses a significant challenge to the adaptation
of the tool to other countries.9–12
Most of the published evidence base on the cost-
effectiveness of cessation and tobacco control has been
produced with no or minimal stakeholder engagement.
Recent work by NICE in the UK suggested that for
complex interventions or strategies, an individual eco-
nomic metric—such as the incremental cost-effectiveness
ratio (which shows how much extra cost decision-makers
have to bear in order to gain one additional
quality-adjusted life year)—is insufficient for decision-
makers to make an investment.7 The study found that
there are a number of other economic metrics that are
deemed important in policy decisions. Moreover, the
study found that lots of different tools were being used
to support purchasing decisions—most of which
required judgements on the part of users. This was
further corroborated by another study in which the
authors consulted with potential stakeholders prior to
developing their economic model.13 This strongly indi-
cates the importance of engaging stakeholders in the
evidence generation process in order to ensure the
wider use of such evidence and to facilitate its transfer-
ability to other countries.
In this paper, we describe EQUIPT (European study
on quantifying utility of investment in protection from
tobacco), a comparative effectiveness research (CER)
study evaluating the cross-context transferability of eco-
nomic evidence on tobacco control.
METHODS AND ANALYSIS
Objective
The overarching aim of EQUIPT is to provide healthcare
policymakers in the EU with bespoke information about
the potential economic and wider returns to be expected
from investing in evidence-based tobacco control
agendas. EQUIPT has the ultimate ambition of underpin-
ning health authority decisions on the development
and/or harmonisation of new strategies for tobacco
control projects for health promotion and disease pre-
vention in the EU by disseminating the ROI concept and
tools across Europe. In the first instance, it will test the
applicability and implementation of the already devel-
oped ROI tool in four other EU member states. Next, it
will test the transferability of the ROI methods to guide
comprehensive tobacco-control policies in other EU
countries.
Study design
EQUIPT is a multicentre, interdisciplinary CER study in
public health. The NICE Tobacco ROI tool—which is a
practical, customisable economic model developed in
England to help make real-world decisions in the context
of local government decision-making—will be adapted to
meet the needs of European decision-makers. Locating
itself in the theory of diffusion of innovation14 and trans-
ferability of economic evidence,10 EQUIPT will co-create
ROI tools to compare the effectiveness of tobacco control
strategies both within and across several EU countries.
We incorporate the ‘inverted cone’ approach
(figure 1) in which: (1) the tip represents the NICE ROI
tool (ie, economic evidence); (2) the middle section
represents the working space (ie, the extent to which this
evidence can be applied in sample countries) and (3)
the top level represents the extended benefit (ie, the
extent to which the policy recommendations coming out
from sample countries can be transferred to other
out-of-sample EU countries). At the heart of this
approach is the translational research framework,15 16
which allows us to utilise different quantitative and
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qualitative methods while benefiting from the experience
and expertise of multidisciplinary consortium members.
Study participants
Four countries in Europe—Germany, Spain, Hungary
and the Netherlands—are included as evidence-
receiving countries (ie, sample countries). The choice of
sample countries is deliberate and represents a wide array
of potential transferability factors, which may then help
to make statements for other European countries outside
this sample. Geographically, this sample covers the whole
continuum from West to East and North to South and
includes a wide range of cultural, behavioural, economic
and other issues which may be considered when transfer-
ring evidence from one country to another. It is antici-
pated that other countries not considered in EQUIPT are
likely to show outcome-relevant characteristics which are
similar to at least one of the sample countries.
Collaborating institutions
This study is funded by the Framework Seven
Programme (FP7) of the European Community and
co-ordinated by the Health Economics Research Group
at Brunel University (UK). The collaborating institutions
in the sample countries are: the Caphri School for
Public Health and Primary Care at Maastricht University
(the Netherlands), the Institute of Health Economics
and Health Care Management at Helmholtz Zentrum
München (Germany); the Syreon Research Institute
(Hungary) and the Centre for Research in Health and
Economics, Pompeu Fabra University (Spain). A wide
range of institutions collaborate to provide multidiscip-
linary inputs required by the study: the National
Institute for Health and Care Excellence (UK), LeLan
Solutions (UK); the National Centre for Smoking
Cessation and Training (UK), the European Network for
Smoking and Tobacco Prevention (Belgium); the
Agency for Quality and Accreditation in Health Care
and Social Welfare (Croatia) and the NHS Bristol
Primary Care Trust (UK) on behalf of Smokefree South
West, Tobacco Free Futures and FRESH North East.
Interventions
EQUIPT will consider the following two groups of
interventions:
1. Smoking cessation interventions to include behavioural
interventions, pharmacotherapy and mixed (behav-
ioural+pharmacotherapy) implemented at the indi-
vidual smoker level.
2. Tobacco control interventions to include smoking pre-
vention and cessation interventions targeted at the
population level.
The specific interventions to be included in the
tool may vary from one sample country to the other
and will be based on the following three criteria:
▸ Analysis of local stakeholders’ views on the
availability and relevance of interventions in
a country.
▸ The interventions are supported by clear evidence
on effectiveness and/or cost-effectiveness,
defined by high-quality ‘comparative’ data coming
from randomised trials, economic evaluations or
real-world observational studies.
▸ The interventions are recommended already, or
have potential for recommendation, by:
A. The country’s Department of Health (DH) or
Health Technology Assessment (HTA) body (if
in existence);
B. Other (similar) EU country’s DH or HTA;
C. NICE in the UK.
Figure 1 ‘Inverted Cone’ design
of EQUIPT for evidence transfer
within the Translational Research
Framework (ROI, Return on
Investment).
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A ‘package’ of interventions (rather than a single inter-
vention) will be evaluated for its ROI. The ‘package’ can
be the current practice (ie, mix of all existing interventions
at their current level of uptake) or alternative practice (ie,
mix of interventions customised to reflect the policy-
makers’ needs, eg, by shifting current uptake or removing
one or more less effective interventions).
Comparators
The comparators will be: (1) baseline, that is, none of
the interventions in place; and (2) current practice, that
is, the existing provision of services.
Data and analysis
Table 1 summarises the tasks, the data and collection
method, and the analysis plan.
In tasks 1 and 2, we will define the contexts in which
tobacco control sits in sample countries in order to
inform the applicability and transferability of the ROI
model to those countries. Desk reviews and stakeholder
interviews will provide data that will help assess the (1)
availability and relevance of different interventions in
sample countries; (2) implications for attuning current
ROI algorithms; (3) needs of local policymakers for
including economic evidence in their decision-making
and (4) factors that are crucial for ROI adoption in
sample countries. We will collect both qualitative data
(eg, a description of different types of cessation services
and tobacco control interventions and views of
policymakers) and quantitative data (eg, population size
and composition (age/gender); smoking and ex-smoking
prevalence; costs of interventions and quit rates; uptake
rates of interventions; productivity impacts of smoking).
The Integrated Change model17 will be used to study the
factors influencing the stakeholders’ intention to use
ROI tools by assessing their awareness of ROI tools,
motives for using such a tool, and future intention and
action plans to use the ROI tools. Both qualitative (open-
ended questionnaires and workshops) as well as quantita-
tive methods will be applied. An assessment of preferred
usability will also be included to enhance future adoption
and implementation of ROI tools.
In task 3, we will adapt the current ROI model to
reflect the needs of decision-makers in sample coun-
tries. This ROI model uses a Markov state transition
model with three states: Smoker, Former Smoker and
Death.8 18 At the start of the simulation, the entire
cohort begins as smokers. With each 1 year cycle, the
cohort is assigned a set of transition probabilities
which allows them to either stay within their current
state or move to one of the other two states. Death is
an absorbing state, meaning that those who enter this
state remain within the state. Within each cycle, both
smokers and former smokers may develop smoking
attributable diseases: lung cancer, coronary heart
disease, myocardial infarction, chronic obstructive pul-
monary disease or stroke. The model provides esti-
mates of both short-term (reduced healthcare use by
Table 1 Task, type of data and analysis plan in EQUIPT
Task Data/collection methods Analysis
1. Comparative assessment of contexts in which
tobacco sits in sample countries
Desk reviews of literature (QL)
Survey data (QN)
Model input parameters (QN)
Narrative literature analysis
Statistical analysis
Expert review of evidence
2. Needs assessment to inform how differential
contexts demand the most appropriate approach
to ROI tool development and usage of the tool
Stakeholder interviews (QL/QN)
Stakeholder consensus meetings (QL)
Statistical analysis on the intention
to use, complemented by content
analysis
Ranking exercise and qualitative
assessment
3. Development of core components and
country-specific components (local models) of
the ROI tool
Economic modelling (QN)
Quality checks and validation (QL/QN)
User-interface (QN)
Deterministic and probabilistic
sensitivity analysis
Validation checklist
Visual basic programming
4. CER, based on local ROI models, to identify
key determinants of policy decisions
Data based on the outcomes of
probabilistic sensitivity analysis
ROI values for each country
Regression-based ‘importance’
analysis
Comparative (statistical) analysis
5. Drawing policy recommendations Stakeholder workshops to
contextualisation of research findings
(QL)
Ranking exercise and qualitative
assessment
6. Testing of transferable policy
recommendations
Additional data from out-of-sample
countries (QN/QL)
Reanalysis of ROI metrics based
on ‘out-of-sample’ data
7. Assessing the most-preferred method for
communicating findings
Online survey (QL/QN) Descriptive statistics, ranking and
qualitative assessment
CER, Comparative effectiveness research; QL, qualitative; QN, quantitative; ROI, Return on Investment.
4 Pokhrel S, et al. BMJ Open 2014;4:e006945. doi:10.1136/bmjopen-2014-006945
Open Access
those stopping smoking, productivity gains, social care
costs avoided due to reduced strokes and reduced
events in both children and adults exposed to passive
smoking) and long-term (smoking attributable deaths,
life years, quality-adjusted life years (QALYs) and
costs) outcomes.
In the Markov state transition model, the prevalence
of smoking-related diseases for smokers and former
smokers are estimated through assessing population
attributable fractions. Costs and utilities are assigned to
each disease. Utility decrements are associated not only
with smoking attributable diseases but also as a result of
being a smoker or a former smoker. Outcomes are
assessed for different population cohorts based on age
(18–85 years) and gender. To obtain population level
estimates, these cohort level estimates are weighted by
the percentage of the smoking population falling into
each age and gender cohort. The model adopts a quasi-
societal perspective in which costs and benefits to the
healthcare system are incorporated in addition to prod-
uctivity gains and reduced need for social care due to
reduced smoking. Costs and outcomes are discounted at
a rate of 3.5% per annum (although a discount rate
between 0% and 10% can be chosen).
In designing the country-specific models in task 3, we
will follow standard guidelines on transferring economic
models to other contexts.19–23 The data to populate these
models will be obtained from published sources and
through additional data analyses. Where available,
country-specific data will be used in the local models, but
we anticipate that some data (eg, intervention effective-
ness) may have to be sourced from the best available evi-
dence (eg, Cochrane review). A user-friendly interface
will be developed using Visual Basic for Applications
(VBA) as the front-end to ensure easy access to the MS
Excel-based models. The models will be validated in line
with best practice guidelines, using an adapted version of
the available checklists.21 24 25 Model outputs will cover a
range of indicators (table 2), although the final indica-
tors and data are to be determined by the outcomes of
tasks 1 and 2.
In task 4, we will conduct a comparative analysis of the
ROI in tobacco control using the outputs from country-
specific models to inform the transferability of results.
This analysis will focus on the burden of tobacco and the
ROI of a ‘comparable-in-content’ package of tobacco
control interventions across sample countries.
In tasks 5 and 6, we will aim to facilitate the transfer of
comparative effectiveness data to other countries in
order to make timely and sensible policy recommenda-
tions, even in the absence of relevant evidence for the
country of interest. This will be done by identifying key
variability factors that, if collected for out-of-sample
countries and used in the ROI model, could provide
similar policy recommendations. Relevant parameters
will be identified through importance analysis techni-
ques which are quantitative approaches for estimating
the impact of changes in input parameters on the
output uncertainty.26 This will be tested by collecting
those variables in a limited number of out-of-sample EU
countries (n=3) as well as feedback from a range of sta-
keholders via workshops. The selection of these coun-
tries will be based on the following criteria: that they are
significantly different from the four sample countries in
terms of stage of tobacco control, health status and use
of HTA in decision-making and that there is a higher
potential to save life years from tobacco control and
quit-support programmes.
Tasks 4–6 will inform the creation of a web-based tool
by combining information on core components and
country-specific components to allow timely and sensible
policy recommendations for decision-makers across
Europe. The country-specific ROI models developed for
sample countries will be redeveloped and reprogrammed
into a unified, web-based tool that can be used by other
EU countries to estimate the ROI of their tobacco control
agenda. Therefore, a fully validated generic web-based
tool will ultimately become the final deliverable product
of this project.
In task 7, we will assess the most preferred method for
communicating study findings to ensure that they are
used to devise tobacco control policies across Europe.
This will be achieved by an online survey and will also
be partly informed by the outcomes from task 1.
Stakeholder engagement
Key stakeholders will be identified right from the begin-
ning (table 3). Stakeholders will provide key inputs to all
Table 2 Examples of intended model outputs to aid decision-making
Costs of tobacco use The economic costs (in €) of tobacco use in the selected area, from both healthcare
and wider perspectives
Avoidable Burden of Disease The number of quality-adjusted life years (QALYs) gained per 1000 population over 2,
5, 10 years and a lifetime, as the result of implementing a package of interventions
Incremental Cost-Effectiveness
Ratio or ICER
Healthcare costs per smoking related death averted, per life year gained and per QALY
gained over 2, 5, 10 years and a lifetime, as the result of implementing a package of
interventions
Benefit Cost Analyses or BCA Healthcare savings benefit–cost ratios, healthcare savings and value of health gains
benefit–cost ratios, as the result of implementing a package of interventions
Net Present Value Analyses or
NPV
Healthcare cost savings per smoker, healthcare cost savings and value of health gains
per smoker, as the result of implementing a package of interventions
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Table 3 Stakeholder engagement in EQUIPT
Method of engagement Engagement purpose Definition of stakeholder Examples
Interviews To learn about the needs of local policymakers for
including economic evidence in their decision-making
and the factors that are crucial for return on
investment (ROI) adoption in sample countries
One or more of the following: health policymakers;
purchasers of services; generators of evidence
leading to policy/procurement/delivery of services;
advocates of health promotion; experts including
clinicians and those specialising in tobacco control;
financial authorities
Two types of stakeholder groups will be targeted:
(1) National and European stakeholders consisting
of policymakers, academics, health authorities,
insurance companies, advocacy groups, ministry of
finance, national committees, clinicians and health
technology assessment (HTA) professionals and
(2) Experts on smoking cessation and HTA
Consensus workshops (to
be held separately in each
sample country)
To discuss and agree on findings and devise a set of
recommendations for the next phase of the project
(adaption of ROI tool in sample countries)
Interviewed stakeholders Interviewed stakeholders
Piloting of a
country-specific ROI tool
To market test the relevance and applicability of the
country-specific ROI tools
Interviewed stakeholders Interviewed stakeholders
Workshop on UK policy
experience
To understand the experience of users of ROI tools
on its applicability, relevance and the extent to which
it has helped in developing policy proposals at local
and regional levels in England. This will inform and
facilitate the research process and encourage
application of the findings of this research in
policymaking
5 regional/local and 5 national UK stakeholders with
previous experience in using the ROI tools
Directors of Public Health, service commissioners
(procurers), local authority representatives (policy
and strategy), tobacco control managers, advocacy
group representatives
International workshop To devise a set of policy proposals relevant to the
out-of-sample countries for the implementation of
evidence-based public health policies and support the
validation of the ROI online tool
Stakeholders from those countries with limited
capacity and budget for the implementation of
evidence-based public health policy (mostly Central
and Eastern European Countries)
Central and Eastern European national
representatives of: policymakers (from ministries of
health, social welfare, finance and science and
education); health professionals (from national
public health institutes, national medical
associations); researchers (from the area of public
health service researchers); insurers/payers; patient
organisations (condition/disease specific), HTA
agencies
Survey To assess the project website using the I-change
model
Relevant stakeholders are those agencies that may
wish to use HTA assessments when making
decisions about which tobacco control strategies/
programmes they wish to recommend for
implementation in their country
Officers from the ministry of health responsible for
Tobacco Control, relevant health organisations (eg,
national Tobacco Control agencies, Heart Societies,
Cancer Societies, Asthma Societies, Regional
Health Authorities, Health Insurance Companies,
HTA groups)
Project website To make project information and results available to
stakeholders
Those who are expected to use the website to
access project information and results
Project partners; potential users of the ROI tools,
media; lay public
Project meetings on
translation into national/
local policy
To reach out to policy, practice and research
communities and to raise awareness and interest for
the new ROI tool
Relevant stakeholders are those agencies that may
wish to use HTA assessments when making
decisions about which tobacco control strategies/
programmes they wish to recommend for
implementation in their country
Stakeholders thus include officers from the ministry
of health responsible for Tobacco Control, relevant
health organisations (eg, national Tobacco Control
agencies, Heart Societies, Cancer Societies,
Asthma Societies, Regional Health Authorities,
Health Insurance Companies, HTA groups)
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stages of the research: needs identification (including
the need for a user-friendly interface), piloting and
testing of ROI concepts and tools in the local setting,
drawing policy implications, testing transferability
assumptions and creating effective dissemination plan.
Ethics and dissemination
The usual ethical issues—maintaining confidentiality,
anonymity and data protection for primary data (eg,
stakeholder interviews) and overall good research practice
—apply to EQUIPT. As this research is led by Brunel
University London, the Brunel University London Research
Ethics Committee (UK) has reviewed this research and
given full ethical clearance. The respective authorities in
sample countries (Ethik-Kommission, Bayerische
Landesärztekammer from Germany, Egészségügyi
Tudományos Tanács, Tudományos És Kutatásetikai
Bizottság from Hungary, and Parc de Salut MAR—Clinical
Research Ethics Committee from Spain and Medisch-
ethische toetsingscommissie (METC) azM/UM from the
Netherlands) have also provided clearance.
EQUIPT has a dedicated work package on dissemin-
ation of findings. The ROI tools will be available for
public download through the project’s website (http://
equipt.ensp.org) together with the accompanying User
Guide, Technical Reports and worked-out examples.
This will form the part of e-learning resources.
The major analytical findings will be disseminated
through peer-reviewed publications in scientific journals,
presentations in conferences, policy briefs and media
briefs.
STATUS OF STUDY
EQUIPT is a 3-year project that started on 1 October
2013 and will end on 30 September 2016.
DISCUSSION
EQUIPT is a rare multidisciplinary study designed to test
the transferability of economic evidence around tobacco
control and will provide evidence-based, practical and
customisable ROI tools to actual decision-makers. The
findings are expected to promote and disseminate the
ROI methods and results to foster evidence-driven
decision-making on comprehensive tobacco control
across Europe.
The primary aim of transferring comparative effective-
ness data to other countries is to make timely and sens-
ible policy recommendations, even in the absence of
relevant evidence for the country of interest. This is
especially beneficial for countries with fewer analytical
resources, where there is a lack of relevant input data to
adapt the ROI model and in which there is a higher
potential to save life years from tobacco control and quit
support strategies.12 There is a limited understanding of
the causes of variability in cost-effectiveness data, and
this presents a key barrier to the transferability of the
economic evaluation results.9 27 Some authors suggest
that “there is a lack of empirical studies which prevents
stronger conclusions regarding which transferability
factors are most important to consider and under which
circumstances.”11 Nevertheless, the transfer of evidence
to other countries may be possible if: (1) we identify
those factors which cause the most variability in the rela-
tive success of tobacco control and quit-support strat-
egies across countries and (2) the countries of interest
are appropriately reflected in the existing data.10
Adapting an economic model may require an evaluation
of those model components that are similar across coun-
tries (core components) and those that vary between
countries (country-specific components). For example,
the EUnetHTA programme “attempt[s] to define and
standardise elements of an HTA” by dividing relevant
information on the technology under assessment “into
standardised pieces, each of which describing one or
more aspects of the technology that is likely to be useful
when considering the adoption or rejection of the tech-
nology.”23 As described above, the EQUIPT study will
follow a stepwise approach to satisfy both conditions.
The design of EQUIPT has several strengths. The
European roll-out of the ROI tool is based on prior
research in the UK. The ‘inverted cone’ approach to
EQUIPT allows us to test the transferability of economic
evidence in a logical pathway. This approach is likely to
avoid any noise in drawing policy implications from the
study results. Stakeholder engagement throughout the
research process highlights the design to be highly rele-
vant to end-users of research findings.
EQUIPT is not free of challenges, however. The
country-specific modelling process will require most
relevant country-specific data, which are often scarce.
A related limitation concerns the availability of effective-
ness data on the full-range activities and strategies recom-
mended by, for example, the WHO, the US Surgeon
General’s report and the Centre for Disease Control. To
aid in the transfer of evidence where such data are not
available, the project is set up to seek to identify those
input data that cause the most variability with respect to
outcomes. In addition, the selection of the four sample
countries is designed to provide a wide representation of
the smoking cessation context within Europe, thereby
aiding in the adaptation of the model to inform policy
within additional countries.
In the worst-case scenario of extreme scarcity of rele-
vant data in a country, EQUIPT will seek an expert panel
to make decisions on the best available evidence for such
a case. By doing so, EQUIPT will highlight the gaps
where more research needs to be conducted and/or
more data need to be collected. Furthermore, while the
transferability of study results to out-of-sample countries
is a complex endeavour, this needs to be communicated
to end-users in simple, practical and customisable web-
based tools. Thanks to the ‘inverted cone’ approach, the
stakeholder engagement as well as modelling experience
gathered in sample countries will inform us to mitigate
such challenges.
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